Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trials
- Resource Type
- Article
- Source
- In
Journal of the American Academy of Dermatology August 2023 89(2):274-282 - Subject
- Language
- ISSN
- 0190-9622